TIMP1 (Tissue inhibitor of metalloproteinases 1)

This review systematically compiles recent advancements in the understanding of TIMP-1's dual functions in cancer, elucidates its mechanistic roles as both a metalloproteinase inhibitor and a cytokine-like factor, and integrates its emerging significance as a biomarker and therapeutic target across diverse cancer types. By synthesizing recent findings, this study seeks to provide novel insights into the translational potential of TIMP-1 in cancer treatment, while examining its prospective implications for therapeutic strategies and clinical interventions.

Six genes (CD36, CLU, FLNA, NOTCH3, TAGLN, TIMP1) were identified as key regulators during ECs phenotypic transition.ConclusionsThis study demonstrates the key roles of disulfidptosis and anoikis, and establishes a novel CCDI model with prognostic value in colon cancer. Additionally, it insights into ECs phenotypic transition and their regulatory genes, provides new therapy targets for colon cancer.

Concurrently, Theranekron® induced transcriptional changes associated with mitochondrial and SMAD-dependent apoptotic pathways. Theranekron® acts as a cell-context-specific modulator, simultaneously regulating PI3K/AKT/PDK1, NF-κB and SMAD pathways to restore ECM integrity and modulate apoptotic signaling pathways in Caco-2 CRC cells, suggesting its potential as a multi-target experimental therapeutic candidate in in vitro CRC models.

Pharmacological BRD4 inhibition or epigenetic PML-SE repression alleviates liver inflammation and fibrosis. In conclusion, PML/BRD4-mediated SE activation via phase separation drives proinflammatory angiocrine signaling in LSECs, initiating the inflammatory cascade and subsequent immune cell recruitment during liver fibrosis.

Although optimization and seeding did not significantly improve the morphology, the additive screen enhanced both the morphology and reproducibility and provided intrinsic cryoprotection. The resulting crystal form proved compatible with soaking-based screening campaigns, providing a robust structural basis for the discovery of TIMP-1 ligands with clinical potential.

This study developed and validated an angiogenesis-related radiogenomics model that accurately predicts OS in ccRCC patients and provides potential therapeutic targets for anti-angiogenic therapy.

We propose a novel NRG-based prognostic signature that accurately predicts outcomes in COAD. The model highlights the interplay between nicotine metabolism, ECM remodeling, and immune responses, highlighting genes and pathways that may inform future therapeutic stratification.

DKA causes a unique inflammatory pattern distinct from inflammatory changes in acute hyperglycemia or T1D-related autoimmunity. Alterations in MMPs and their tissue inhibitors play a dominant role in this inflammatory profile.

The TIMP-1 immunoassay, modified for the Alinityi platform, detected TIMP-1 at physiologically relevant ranges. Future clinical development of the assay will focus on its clinical utility in various cardiac cohorts as a potential biomarker of fibrotic heart disease.

In addition, a significant correlation between nitrosative stress, glycemia, inflammation, glycogen depletion, TIMP-1, and collagen deposition (fibrosis) was observed. These findings demonstrate that diabetes adversely affects hepatic glycogen stores and causes liver tissue injury, as well as upregulating the TNF-α/iNOS/TIMP-1 fibrosis axis while being protected by metformin.

In conclusion, benzydamine exerted anti-MMP-9 actions through inhibition of ERK MAPK and NF-κB activation under the high-glucose condition. This study revealed additional anti-monocytic properties of benzydamine in its potential for novel anti-inflammatory therapy.

ITLN1 inhibits CRC progression by inactivating the Wnt/β-catenin signaling pathway and reprogramming macrophages toward a tumor-suppressive M1 phenotype, highlighting its potential as a therapeutic target.